BREAKING
Q32 Bio Inc. (QTTB) Reports Q4 Earnings 50 seconds ago BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 7 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 12 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 14 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 18 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 24 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 30 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 37 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 41 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 44 minutes ago Q32 Bio Inc. (QTTB) Reports Q4 Earnings 50 seconds ago BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 7 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 12 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 14 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 18 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 24 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 30 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 37 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 41 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 44 minutes ago
ADVERTISEMENT
Breaking News

Yext (YEXT) Q4 Earnings: $0.15 EPS as Revenue Flatlines at $112M

Yext reports Q4 adjusted EPS of $0.15, matching prior quarter, as revenue stalls at $112M year-over-year.

$CRM $GOOGL $YEXT March 10, 2026 2 min read
NYSE
$CRM · Earnings

Yext reports Q4 adjusted EPS of $0.15, matching prior quarter, as revenue stalls at $112M year-over-year.

Earnings Per Share (adj.)
$0.15
estimate N/A
Revenue
$112.0M
estimate N/A

Yext holds the line. Yext, Inc (NYSE: YEXT) reported adjusted EPS of $0.15 for Q4 fiscal 2026, matching the prior quarter’s $0.14 and the year-ago result of $0.14. The software infrastructure provider delivered consistent profitability in its fourth consecutive quarter of positive adjusted earnings. GAAP EPS came in at $0.03, while adjusted EBITDA reached $29 million.

Revenue flatlines year-over-year. Revenue of $112 million was essentially unchanged from the year-ago quarter’s $111.998 million, representing a YoY change of $0.00. The stagnant top line marks a sharp deceleration from Q3 fiscal 2025’s $113.1 million, suggesting the company is struggling to reignite growth in its digital presence platform business. Trading volume reached 3.04 million shares as the stock closed at $5.58, well below its 52-week high of $9.20.

What to Watch: The company filed an 8-K and press release on March 9. Investors should scrutinize management’s fiscal 2027 guidance and any commentary on customer retention metrics when the full earnings call transcript becomes available—revenue growth remains the critical missing piece in Yext’s turnaround narrative.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT